Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Novel delivery of an antisense oligonucleotide to the brain for Huntington Disease

EF 2018-19

Résumé
Huntington Disease (HD) is fatal genetic brain disorder whose symptoms include cognitive decline and uncontrollable movement. In mouse models of HD, it is possible to reverse these symptoms by lowering levels of the disease-causing mutant protein, huntingtin. Currently, a clinical trial is testing a treatment called HTTRX in HD patients, but to reach the brain, this drug must be injected into the fluid surrounding the spinal cord. This delivery method is invasive and risky. When the drug is delivered this way, it does not distribute across the entire brain or reach the rest of the body. Some brain regions that are poorly reached are known to be damaged in HD and the source of debilitating symptoms. Delivering the drug by injecting it into the bloodstream would allow it to reach other parts of the body. The challenge to this approach is that the brain is protected by a structure called the blood-brain barrier (BBB) which does not allow foreign compounds to reach the brain. There are several proteins known to cross the BBB as part of their normal function. These proteins can be used as a “Trojan Horse” to shuttle other molecules into the brain. In this project, I will attach a drug similar to HTTRX to one of these proteins, and test in mice whether this hybrid molecule can reach the brain when injected into the blood. Then, I will test whether it can lower the levels of the mutant protein that causes HD. Delivering drugs like HTTRX to the brain through the blood could improve treatments for HD patients, because the drug delivery would be less invasive, and would reach target regions of the brain, as well as the rest of the body. If successful, this approach could be modified for use with other similar drugs and thus could be used to treat many genetic brain diseases.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406375
Name
Findlay Black Hailey R
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel delivery of an antisense oligonucleotide to the brain for Huntington Disease
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antisense Oligonucleotide; Blood Brain Barrier; Drug Delivery; Huntington Disease; Therapeutics
Abstract
Huntington Disease (HD) is fatal genetic brain disorder whose symptoms include cognitive decline and uncontrollable movement. In mouse models of HD, it is possible to reverse these symptoms by lowering levels of the disease-causing mutant protein, huntingtin. Currently, a clinical trial is testing a treatment called HTTRX in HD patients, but to reach the brain, this drug must be injected into the fluid surrounding the spinal cord. This delivery method is invasive and risky. When the drug is delivered this way, it does not distribute across the entire brain or reach the rest of the body. Some brain regions that are poorly reached are known to be damaged in HD and the source of debilitating symptoms. Delivering the drug by injecting it into the bloodstream would allow it to reach other parts of the body. The challenge to this approach is that the brain is protected by a structure called the blood-brain barrier (BBB) which does not allow foreign compounds to reach the brain. There are several proteins known to cross the BBB as part of their normal function. These proteins can be used as a “Trojan Horse” to shuttle other molecules into the brain. In this project, I will attach a drug similar to HTTRX to one of these proteins, and test in mice whether this hybrid molecule can reach the brain when injected into the blood. Then, I will test whether it can lower the levels of the mutant protein that causes HD. Delivering drugs like HTTRX to the brain through the blood could improve treatments for HD patients, because the drug delivery would be less invasive, and would reach target regions of the brain, as well as the rest of the body. If successful, this approach could be modified for use with other similar drugs and thus could be used to treat many genetic brain diseases.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Findlay Black, Hailey R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~